Objective. The aim of this phase II study was to evaluate the efficac y and tox icity of gemcitabine, carboplatin, and paclitaxel (GCP) combination as salvage t herapy in patients with relapsed ovarian or peritoneal c...
详细信息
Objective. The aim of this phase II study was to evaluate the efficac y and tox icity of gemcitabine, carboplatin, and paclitaxel (GCP) combination as salvage t herapy in patients with relapsed ovarian or peritoneal cancer who had previously received platinum-based chemotherapy. Patients and Methods. Patients with prog ressive ovarian or peritoneal carcinoma who had previously received platinum-based chemotherapy were enrolled. Gemcitabine was administered at 80 0 mg/m2 as a 30-min intravenous infusion on days 1 and 8; carboplatin (AUC of 5 ) and paclitaxel (175 mg/m2) were administered as 60-min and 3-h intravenous i nfusions, respectively, on day 1. Treatment cycles were repeated every 3 weeks f or a maximum of nine cycles. Results. Twenty patients (ovarian carcinoma, 19; pe ritoneal carcinoma, 1) received this triplet regimen as salvage therapy. All the patients had previously received at least one platinumbased regimen for chemoth erapy and 17 of them had received platinum plus paclitaxel. The median number of previous regimens was 2 (range, 1-4), and the median platinum-free interval w as 9 months (range, 1-18). A total of 130 cycles were administered with a media n of six cycles per patient (range, 3-9). The overall response rate was 75%, i ncluding 12 complete responses (60%; 95%confidence interval mai n toxicity, with leukopenia being themost prominent (grade 3/4 toxicity in 35%p atients), followed by thrombocytopenia in 20%patients. In addition, 35%patient s had grade 3 anemia. All the toxicities were manageable and the patients recove red fully. Among nonhematological toxicities, the only notable one was grades 2 and 3 hepatic toxicity seen in two and one patients, respectively, necessitating a decrease in the pa
暂无评论